awmsg logo



melatonin (Slenyto®)


Reference No. 3947

Publication date:
01/04/2019


Appraisal information

melatonin (Slenyto®) 1 mg prolonged-release tablet
melatonin (Slenyto®) 5 mg prolonged-release tablet


Company: Flynn Pharma Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/03/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, melatonin (Slenyto®) cannot be endorsed for use within NHS Wales for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
Statement of Advice (SOA)
Download